Clinical trial · Interventional
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
NCT06527495CI-TRIAL-00079232unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sorafenib | Drug | Sorafenib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sorafenib
- description
- Sorafenib 200 - 400 mg twice daily
- interventionNames
- Drug: Sorafenib
Primary outcomes (2)
- measure
- Vascular Endothelial Growth Factor A (VEGFA) genotyping
- timeFrame
- At Baseline, 3 month, and 6 month after treatment.
- description
- Genetic polymorphism of VEGFA
- measure
- Kinase insert domain receptor (KDR) genotyping
- timeFrame
- At Baseline, 3 month, and 6 months after treatment.
- description
- Genetic polymorphism of KDR
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age of all studied subjects ≥ 18 years old * All patients with hepatocellular carcinoma will be included in group I. * Patients not treated with systemic TKIs Exclusion Criteria: * Patients presented with liver tumors other than HCC. * Patients with Child-Pugh grade C for liver function. * Patients with other malignancies. * Patients with chronic inflammatory disorders. * Patients with severe organ dysfunction such as heart, lung, and kidney. * Patients who cannot tolerate or are allergic to sorafenib. * Patients with severe coagulation dysfunction were uncorrectable. * Age less than 18 years old.
References
Publications (0)
Data not yet available
No reference posted for this study.